Treatment of metastatic melanoma in the brain with temozolomide and thalidomide

被引：29

作者：

Hwu, WJ

Raizer, J

Panageas, KS

Lis, E

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

来源：

LANCET ONCOLOGY | 2001年 / 2卷 / 10期

关键词：

D O I：

10.1016/S1470-2045(01)00522-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：634 / 635

页数：2

共 6 条

[1]

Brock CS, 1998, CANCER RES, V58, P4363

[2]

HWU W, 2001, P AN M AM SOC CLIN, V20, pA357

[3] Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [J].

Middleton, MR ;

Grob, JJ ;

Aaronson, N ;

Fierlbeck, G ;

Tilgen, W ;

Seiter, S ;

Gore, M ;

Aamdal, S ;

Cebon, J ;

Coates, A ;

Dreno, B ;

Henz, M ;

Schadendorf, D ;

Kapp, A ;

Weiss, J ;

Fraass, U ;

Statkevich, P ;

Muller, M ;

Thatcher, N .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :158-166

[4]

RICHARDSON P, 2001, CANC PPO UPDATES, V15, P1

[5]

ZIMM S, 1981, CANCER, V48, P384, DOI 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO

[6]

2-8

← 1 →